[go: up one dir, main page]

AR109552A1 - Análogos de insulina con afinidad reducida para el receptor de insulina y uso de los mismos - Google Patents

Análogos de insulina con afinidad reducida para el receptor de insulina y uso de los mismos

Info

Publication number
AR109552A1
AR109552A1 ARP170102640A ARP170102640A AR109552A1 AR 109552 A1 AR109552 A1 AR 109552A1 AR P170102640 A ARP170102640 A AR P170102640A AR P170102640 A ARP170102640 A AR P170102640A AR 109552 A1 AR109552 A1 AR 109552A1
Authority
AR
Argentina
Prior art keywords
insulin
amino acid
chain
receiver
same
Prior art date
Application number
ARP170102640A
Other languages
English (en)
Inventor
Norbert Tennagels
Stefan Guessregen
Marcus Korn
Sung Youb Jung
In Young Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd, Sanofi Aventis Deutschland filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR109552A1 publication Critical patent/AR109552A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un análogo de insulina, que comprende por lo menos una modificación en aminoácidos seleccionados del grupo que consiste en el decimosexto aminoácido de la cadena B, el vigésimo quinto aminoácido de la cadena B, el decimocuarto aminoácido de la cadena A, y el decimonoveno aminoácido de la cadena A de insulina nativa. Reivindicación 16: Un ácido nucleico aislado que codifica el análogo de insulina de acuerdo con cualquiera de las reivindicaciones 1 a 15. Reivindicación 17: Un vector de expresión recombinante que comprende el ácido nucleico de acuerdo con la reivindicación 16. Reivindicación 18: Un transformante que comprende el vector de expresión recombinante de acuerdo con la reivindicación 17. Reivindicación 22: Una composición farmacéutica para el tratamiento de la diabetes que comprende el análogo de insulina de acuerdo con cualquiera de las reivindicaciones 1 a 15 como un componente activo.
ARP170102640A 2016-09-23 2017-09-25 Análogos de insulina con afinidad reducida para el receptor de insulina y uso de los mismos AR109552A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160122484 2016-09-23

Publications (1)

Publication Number Publication Date
AR109552A1 true AR109552A1 (es) 2018-12-19

Family

ID=61690584

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102640A AR109552A1 (es) 2016-09-23 2017-09-25 Análogos de insulina con afinidad reducida para el receptor de insulina y uso de los mismos

Country Status (12)

Country Link
US (1) US11396534B2 (es)
EP (1) EP3517544B1 (es)
JP (1) JP7158378B2 (es)
KR (1) KR102698929B1 (es)
CN (1) CN110546161B (es)
AR (1) AR109552A1 (es)
AU (1) AU2017332408B2 (es)
BR (1) BR112019005637A2 (es)
CA (1) CA3037844A1 (es)
RU (1) RU2764197C1 (es)
TW (1) TWI774694B (es)
WO (1) WO2018056764A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3551209T1 (sl) 2016-12-09 2021-10-29 Akston Biosciences Corp Inzulin-FC fuzije in postopki uporabe
TWI798209B (zh) * 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
LT4011908T (lt) 2018-06-29 2023-09-11 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
EP3893934B1 (en) * 2018-12-11 2025-09-10 Sanofi Insulin conjugates
AU2020407365B2 (en) 2019-12-19 2023-09-21 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2536040A1 (de) 1975-08-13 1977-02-24 Hoechst Ag Insulin-analoga mit biologischer wirkung
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
IL93282A (en) * 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5422339A (en) 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
CA2208095C (en) * 1994-12-29 2006-11-28 Bio-Technology General Corp. Generation of human insulin
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
CN1571676A (zh) 2001-10-19 2005-01-26 伊莱利利公司 Glp－1和胰岛素的双相混合物
US7737260B2 (en) 2003-11-13 2010-06-15 Hanmi Pharm. Co., Ltd Protein complex using an immunoglobulin fragment and method for the preparation thereof
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
CA2518776A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
US20060241019A1 (en) 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
MX2007016314A (es) 2005-06-16 2008-03-10 Nektar Therapeutics Al Corp Conjugados que tienen un enlace degradable y reactivos polimericos utiles en la preparacion de tales conjugados.
CN101243190B (zh) 2005-08-16 2015-05-13 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
WO2008015099A2 (en) 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
JP5864834B2 (ja) * 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
EP2017288A1 (en) 2007-07-16 2009-01-21 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
WO2009010428A1 (en) 2007-07-16 2009-01-22 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
EP2178912B1 (en) 2007-08-15 2015-07-08 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
EP2229406B1 (de) * 2008-01-09 2015-04-22 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
JP5749155B2 (ja) * 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
EP2376520B1 (en) * 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
NZ595344A (en) 2009-03-27 2013-09-27 Glaxo Group Ltd Drug fusions and conjugates
WO2011028813A2 (en) 2009-09-01 2011-03-10 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
WO2011058083A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
WO2011075606A2 (en) 2009-12-18 2011-06-23 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012098462A1 (en) 2011-01-20 2012-07-26 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
MY180513A (en) 2011-03-02 2020-12-01 Oerlikon Surface Solutions Ag Trubbach Sliding component coated with metal-comprising carbon layer for improving wear and friction behavior by tribological applications under lubricated conditions
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
CN103582801B (zh) 2011-05-03 2015-11-25 帝人芳纶有限公司 防弹板
BR112013030933A2 (pt) 2011-06-02 2018-04-24 Prolor Biotech Inc agonistas do receptor de glp-1/glucágon de ação prolongada
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CA2838503C (en) 2011-06-10 2020-02-18 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
ES2710356T3 (es) 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
US9165768B2 (en) 2011-12-16 2015-10-20 Lg Innotek Co., Ltd. Method for deposition of silicon carbide and silicon carbide epitaxial wafer
EP2804621A4 (en) 2012-01-20 2015-11-18 Univ Case Western Reserve GLUTAMINE-SAFE STABILIZED INSULIN ANALOG
JP6382111B2 (ja) 2012-03-01 2018-08-29 ノヴォ ノルディスク アー／エス Ｎ末端改変オリゴペプチド及びその使用
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MY197849A (en) 2012-11-06 2023-07-20 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
MY186990A (en) 2013-02-26 2021-08-26 Hanmi Pharm Ind Co Ltd Novel insulin analog and use thereof
TR201910929T4 (tr) 2013-02-26 2019-08-21 Hanmi Pharm Ind Co Ltd Bölgeye özel insülin konjugatı.
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AU2014208184A1 (en) 2013-07-29 2015-02-12 Berkeley Information Technology Pty Ltd Systems and methodologies for managing document access permissions
MA43289B1 (fr) 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20160001391A (ko) * 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) * 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
KR101676542B1 (ko) 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
KR20170036643A (ko) * 2015-09-24 2017-04-03 한미약품 주식회사 인슐린의 제조 방법
TWI798209B (zh) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途

Also Published As

Publication number Publication date
JP7158378B2 (ja) 2022-10-21
CN110546161B (zh) 2024-01-26
TW201813977A (zh) 2018-04-16
US20190300593A1 (en) 2019-10-03
RU2764197C1 (ru) 2022-01-14
TWI774694B (zh) 2022-08-21
CN110546161A (zh) 2019-12-06
EP3517544A1 (en) 2019-07-31
EP3517544A4 (en) 2020-06-03
EP3517544B1 (en) 2025-01-08
JP2019531075A (ja) 2019-10-31
CA3037844A1 (en) 2018-03-29
US11396534B2 (en) 2022-07-26
WO2018056764A1 (ko) 2018-03-29
KR102698929B1 (ko) 2024-08-27
AU2017332408A1 (en) 2019-05-16
EP3517544C0 (en) 2025-01-08
AU2017332408B2 (en) 2022-02-10
KR20180033105A (ko) 2018-04-02
BR112019005637A2 (pt) 2019-07-30

Similar Documents

Publication Publication Date Title
AR109552A1 (es) Análogos de insulina con afinidad reducida para el receptor de insulina y uso de los mismos
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
AR102712A1 (es) Agonistas parciales del receptor de insulina
MX2015000990A (es) Analogos del glucagon.
WO2015106269A3 (en) Rapid action insulin formulations and pharmaceutical delivery systems
CL2018000215A1 (es) Uso de variantes de péptido natriuretico de tipo c para tratar displasia esquelética.
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
MX351865B (es) Composiciones de raav-guanilato ciclasa y metodos para el tratamiento de la amaurosis congenita de leber 1 (lca1).
BR112016016578A2 (pt) Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
UY36870A (es) Análogos de insulina novedosos
GT201700150A (es) Derivados de glucagón con estabilidad mejorada
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CR20170114A (es) N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b
BR112016000565A2 (pt) polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma
MX389999B (es) Estabilizadores de mastocitos para el tratamiento de hipercitoquinemia e infeccion viral
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
GT201700224A (es) Proteína de unión a rgma y su uso
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
EA202290001A1 (ru) Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
AR118481A1 (es) Vector y método para tratar el síndrome de angelman
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods